Sparton to Provide Manufacturing Services to AIT Therapeutics


Reading time ( words)

AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, has begun commercial development for its ventilator compatible NO generator and delivery system with Sparton Corporation. AIT and Sparton expect to complete the process in approximately 6 months, and AIT will make a 510(k) submission to the FDA shortly thereafter.

“AIT and Sparton have been working together on the NO generator and delivery system for more than a year with excellent results to date,” said Steven Lisi, chairman and chief executive officer of AIT Therapeutics. “We are looking forward to a 510(k) submission to the FDA early next year for the ventilator compatible system, as well as initiating studies in both bronchiolitis and NTM with the commercial mask compatible system in 2019. Over the past 18 months the AIT team has successfully executed on three separate programs, and we are looking forward to our efforts resulting in improving the lives of patients over the next several years.”

“Sparton is proud to play a key role in bringing a product that will positively impact the health of many people to the market,” said Mike Gaul, group vice president, Manufacturing and Design Services. "We look forward to our continued partnership with AIT through the regulatory and manufacturing processes.”

About Nitric Oxide (NO)

Nitric Oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions.  In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm.  In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.

About AIT Therapeutics Inc.

AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). 

About Sparton

Sparton Corporation, now in its 119th year, is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, field service and refurbishment. The primary markets served are Medical & Biotechnology, Military & Aerospace and Industrial & Commercial. Headquartered in Schaumburg, Illinois, Sparton currently has thirteen manufacturing locations and engineering design centers worldwide. Sparton’s website may be accessed here.

Share

Print


Suggested Items

Automation and the Smart Factory: Introduction to Industry 4.0

03/20/2019 | Happy Holden, I-Connect007
The characteristics of successful automation application in manufacturing depend on how well business and technical management understand and promote the strategies, tactics, and philosophies used in modern manufacturing. This article briefly outlines the background of computer-integrated manufacturing (CIM) and its evolution to Industry 4.0 and smart factories.

RTW IPC APEX EXPO 2019: Standards Updates: IPC-7093 & IPC-7530

03/13/2019 | Real Time with...IPC
Ray Prasad, IPC Hall of Famer and chairman for multiple committees, gives Guest Editor Joe Fjelstad an update on two IPC standards: IPC-7093 on bottom-termination components (BTCs), and IPC-7530 progress with reflow characterization. Prasad talks about the many challenges in dealing with BTCs, including circuit/board design, manufacturing, voiding, connections (or lack thereof), warpage, and reliability. He also speaks about no-clean flux and its challenges.

Nate Ramanathan on Choosing a Prototype Partner and Production Supplier

03/12/2019 | Nolan Johnson, I-Connect007
AEye, a developer of perception systems for autonomous vehicles, has transitioned from initial engineering development into the final design for production and manufacturing of very large quantities. In an interview with I-Connect007, Nate Ramanathan, VP of operations at AEye, speaks about the criteria and his perspective on selecting vendors.



Copyright © 2019 I-Connect007. All rights reserved.